Relationship of anifrolumab pharmacokinetics with efficacy and safety in patients with systemic lupus erythematosus

OBJECTIVES: To characterize the relationship of anifrolumab pharmacokinetics with efficacy and safety in patients with moderate to severe SLE despite standard therapy, using pooled data from two phase 3 trials. METHODS: TULIP-1 and TULIP-2 were randomized, placebo-controlled, 52-week trials of intra...

Descripción completa

Detalles Bibliográficos
Autores principales: Chia, Yen Lin, Zhang, Jianchun, Tummala, Raj, Rouse, Tomas, Furie, Richard A, Morand, Eric F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9071514/
https://www.ncbi.nlm.nih.gov/pubmed/34528084
http://dx.doi.org/10.1093/rheumatology/keab704

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9071514/
https://www.ncbi.nlm.nih.gov/pubmed/34528084
http://dx.doi.org/10.1093/rheumatology/keab704

Ejemplares similares